1. Home
  2. INCR vs SCLX Comparison

INCR vs SCLX Comparison

Compare INCR & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$0.83

Market Cap

47.4M

Sector

Health Care

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$10.64

Market Cap

52.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCR
SCLX
Founded
1994
2011
Country
Israel
United States
Employees
N/A
30
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.4M
52.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
INCR
SCLX
Price
$0.83
$10.64
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
39.5K
66.6K
Earning Date
05-01-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.54
$122.52
Revenue Next Year
$41.75
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$3.95
52 Week High
$1.77
$34.27

Technical Indicators

Market Signals
Indicator
INCR
SCLX
Relative Strength Index (RSI) 58.78 74.60
Support Level $0.86 $7.73
Resistance Level $0.93 $12.30
Average True Range (ATR) 0.06 1.11
MACD 0.01 0.55
Stochastic Oscillator 77.33 76.48

Price Performance

Historical Comparison
INCR
SCLX

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: